Canopy Growth Emphasizes Strong Commitment to Medical Cannabis

Visit the Canopy Growth Corp Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

Medical Cannabis Leadership from Canopy Growth and Subsidiary Spectrum Cannabis

Clinical Trials, Price Excise Tax Relief, and World-class Leadership Underpin Commitment to Patients and Healthcare Professionals

SMITHS FALLS, ON, June 12, 2018 /CNW/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the “Company” or “Canopy Growth”) is pleased to provide the following updates on its medical cannabis program and to re-affirm its strong commitment to medical cannabis, the patients who depend on it, and the Healthcare Professionals who prescribe it.


Marking a major milestone for medical cannabis in Canada, a Phase IIb “in-human” clinical trial application was submitted by Canopy Health Innovations Inc. to evaluate the use of medical

... read more at: